New drug combo aims to protect kidneys in heart patients
NCT ID NCT07304817
First seen Jan 11, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This study tests whether a new drug, vicadrostat, works differently than the older drug spironolactone when both are taken with empagliflozin. About 100 adults with chronic kidney disease and heart disease or heart failure will take one of the two combinations for 26 weeks. Researchers will measure changes in kidney function and look at protein patterns in blood and urine to understand how each drug affects the kidneys.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Delphinium
RECRUITINGGroningen, Provincie Groningen, 9713GZ, Netherlands
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University Medical Center Groningen
RECRUITINGGroningen, Provincie Groningen, 9713GZ, Netherlands
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.